{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T16:42:55Z","timestamp":1786725775706,"version":"build-2736575974"},"reference-count":88,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction:<\/jats:title>\n                    <jats:p>\n                      This study evaluated the efficacy of novel \u03b2-lactam\/\u03b2-lactamase (N\u03b2L\/\u03b2LIs) combination\n                      <jats:italic toggle=\"yes\">against Enterobacteriaceae<\/jats:italic>\n                      and\n                      <jats:italic toggle=\"yes\">Pseudomonas aeruginosa<\/jats:italic>\n                      infections.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>\n                      We searched CENTRAL, MEDLINE, Embase, CINAHL, Google Scholar, and clinical trial registries through April 20, 2025, and included randomized controlled trials (RCTs) comparing N\u03b2L\/\u03b2LIs with best available therapy (BAT). Pediatric, noncomparative, and\n                      <jats:italic toggle=\"yes\">in vitro<\/jats:italic>\n                      studies were excluded. We performed meta-analyses using random effects models to calculate odds ratios (OR) with 95% confidence intervals (CIs), summarized using GRADE methodology. We included 22 RCTs with 11,238 participants. All RCTs except one were conducted worldwide between 2012 and 2025. Approximately 52% of participants used novel \u03b2-lactamase inhibitors. Risk of bias (RoB) was assessed using the RoB 2 tool.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      N\u03b2L\/\u03b2LIs were as effective as BAT (OR 1.12, 95% CI 0.95\u20131.31;\n                      <jats:italic toggle=\"yes\">I<\/jats:italic>\n                      <jats:sup>2<\/jats:sup>\n                      = 29%; 21 studies, 7630 participants). In multidrug resistance (MDR) infections, N\u03b2L\/\u03b2LIs showed a trend toward benefit (OR 1.23, 95% CI 0.95\u20131.58;\n                      <jats:italic toggle=\"yes\">I<\/jats:italic>\n                      \u00b2 =12%; 17 RCTs, 1713 participants). For microbiological cure, N\u03b2L\/\u03b2LIs were superior (OR 1.33, 95% CI 1.06\u20131.66;\n                      <jats:italic toggle=\"yes\">I<\/jats:italic>\n                      <jats:sup>2<\/jats:sup>\n                      = 68%; 22 studies), mainly due to improved efficacy in complicated tract infections. Safety outcomes were comparable between groups.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>\n                      Novel \u03b2L\/-\u03b2LIs are as effective as BAT in treating\n                      <jats:italic toggle=\"yes\">Enterobacteriaceae<\/jats:italic>\n                      and\n                      <jats:italic toggle=\"yes\">P. aeruginosa<\/jats:italic>\n                      infections, including MDR strains.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/jgid.jgid_133_25","type":"journal-article","created":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T12:10:11Z","timestamp":1778501411000},"page":"54-68","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Examining the Clinical Efficacy of Novel Beta-Lactam and Beta-Lactamase Inhibitor Antibiotics: A Systematic Review and Meta-Analysis"],"prefix":"10.4103","volume":"18","author":[{"given":"Mohamed Hamed","family":"Elkholi","sequence":"first","affiliation":[{"name":"Department of Intensive Care, Rashid Hospital, Dubai, United Arab Emirates"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed Ibrahim","family":"Shoaib","sequence":"additional","affiliation":[{"name":"Department of Intensive Care, Rashid Hospital, Dubai, United Arab Emirates"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeyad","family":"Alrais","sequence":"additional","affiliation":[{"name":"Department of Intensive Care, Rashid Hospital, Dubai, United Arab Emirates"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khalid Omar","family":"Hassan","sequence":"additional","affiliation":[{"name":"Department of Intensive Care, Rashid Hospital, Dubai, United Arab Emirates"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,5,6]]},"reference":[{"key":"R1-20260625","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1097\/QCO.0000000000000501","article-title":"Update on epidemiology and appropriate treatment of life-threatening Gram-negative infections","volume":"31","author":"Bassetti","year":"2018","journal-title":"Curr Opin Infect Dis"},{"key":"R2-20260625","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1378\/chest.14-2171","article-title":"Antimicrobial resistance in hospital-acquired Gram-negative bacterial infections","volume":"147","author":"Mehrad","year":"2015","journal-title":"Chest"},{"key":"R3-20260625","doi-asserted-by":"crossref","first-page":"116949","DOI":"10.1016\/j.diagmicrobio.2025.116949","article-title":"Understanding antimicrobial resistance (AMR) mechanisms and advancements in AMR diagnostics","volume":"113","author":"Sinha","year":"2025","journal-title":"Diagn Microbiol Infect Dis"},{"key":"R4-20260625","doi-asserted-by":"crossref","first-page":"100947","DOI":"10.1016\/j.lanmic.2024.07.010","article-title":"Antimicrobial resistance: A concise update","volume":"6","author":"Ho","year":"2025","journal-title":"Lancet Microbe"},{"key":"R5-20260625","doi-asserted-by":"crossref","first-page":"100902","DOI":"10.1016\/S2666-5247(24)00134-4","article-title":"WHO global research priorities for antimicrobial resistance in human health","volume":"5","author":"Bertagnolio","year":"2024","journal-title":"Lancet Microbe"},{"key":"R6-20260625","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1080\/14656566.2019.1660772","article-title":"The latest advances in \u03b2-lactam\/\u03b2-lactamase inhibitor combinations for the treatment of Gram-negative bacterial infections","volume":"20","author":"Papp-Wallace","year":"2019","journal-title":"Expert Opin Pharmacother"},{"key":"R7-20260625","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1039\/D1MD00200G","article-title":"\u03b2-Lactam antibiotic targets and resistance mechanisms: From covalent inhibitors to substrates","volume":"12","author":"Mora-Ochomogo","year":"2021","journal-title":"RSC Med Chem"},{"key":"R8-20260625","doi-asserted-by":"crossref","first-page":"141","DOI":"10.4062\/biomolther.2023.008","article-title":"Structural insights for \u03b2-lactam antibiotics","volume":"31","author":"Kim","year":"2023","journal-title":"Biomol Ther (Seoul)"},{"key":"R9-20260625","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.clinthera.2016.01.018","article-title":"Ceftazidime-Avibactam: A Novel Cephalosporin\/\u03b2-Lactamase Inhibitor Combination for the Treatment of Resistant Gram-negative Organisms","volume":"38","author":"Sharma","year":"2016","journal-title":"Clin Ther"},{"key":"R10-20260625","doi-asserted-by":"crossref","first-page":"e0172123","DOI":"10.1128\/aac.01721-23","article-title":"Crystal structure of the class A extended-spectrum beta-lactamase CTX-M-96 in complex with relebactam at 1.03 Angstrom resolution","volume":"68","author":"Ghiglione","year":"2024","journal-title":"Antimicrob Agents Chemother"},{"key":"R11-20260625","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1002\/phar.4629","article-title":"Aztreonam-avibactam: The dynamic duo against multidrug-resistant gram-negative pathogens","volume":"44","author":"Al Musawa","year":"2024","journal-title":"Pharmacotherapy"},{"key":"R12-20260625","doi-asserted-by":"crossref","first-page":"3682","DOI":"10.1021\/acs.jmedchem.5b00127","article-title":"Discovery of a Cyclic Boronic Acid \u03b2-Lactamase Inhibitor (RPX7009) with Utility vs Class A Serine Carbapenemases","volume":"58","author":"Hecker","year":"2015","journal-title":"Journal of medicinal chemistry"},{"key":"R13-20260625","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1080\/14787210.2020.1756775","article-title":"Meropenem\/vaborbactam: a next generation \u03b2-lactam \u03b2-lactamase inhibitor combination","volume":"18","author":"Novelli","year":"2020","journal-title":"Expert review of anti-infective"},{"key":"R14-20260625","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1093\/infdis\/jiaf203","article-title":"Cefepime-Taniborbactam-a Novel Combination Therapy for Multidrug-Resistant Pathogens","volume":"232","author":"Watkins","year":"2025","journal-title":"J Infect Dis"},{"key":"R15-20260625","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s40265-013-0168-2","article-title":"Ceftolozane\/tazobactam: A novel cephalosporin\/\u03b2-lactamase inhibitor combination with activity against multidrug-resistant Gram-negative bacilli","volume":"74","author":"Zhanel","year":"2014","journal-title":"Drugs"},{"key":"R16-20260625","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1080\/17425255.2024.2427310","article-title":"Cefepime\/Enmetazobactam: a microbiological, pharmacokinetic, pharmacodynamic, and clinical evaluation","volume":"21","author":"Darlow A.Hope","year":"2024","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"R17-20260625","doi-asserted-by":"crossref","first-page":"220119","DOI":"10.1183\/16000617.0119-2022","article-title":"New antibiotics for Gram-negative pneumonia","volume":"31","author":"Bassetti","year":"2022","journal-title":"European respiratory review"},{"key":"R18-20260625","doi-asserted-by":"crossref","first-page":"10.1007\/s40121","DOI":"10.1007\/s40121-021-00412-y","article-title":"Cost. Analysis of New Antibiotics to Treat Multidrug-Resistant Bacterial Infections: Mind the Gap","volume":"10","author":"Yahav","year":"2021","journal-title":"Infectious diseases and therapy"},{"key":"R19-20260625","article-title":"Chapter 3: Defining the criteria for including studies and how they will be grouped for the synthesis (chapter last updated August 2023)","author":"McKenzie","journal-title":"Cochrane Handbook for Systematic Reviews of Interventions Version 6.5"},{"key":"R20-20260625","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: An updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"R21-20260625","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: An updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"R22-20260625","journal-title":"The EndNote Team"},{"key":"R24-20260625","first-page":"14898","article-title":"RoB 2: A revised tool for assessing risk of bias in randomized trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"R28-20260625","article-title":"Chapter 12: Synthesizing and presenting findings using other methods (chapter last updated October 2019)","author":"McKenzie","journal-title":"Cochrane Handbook for Systematic Reviews of Interventions Version 6.5 (updated August 2024)"},{"key":"R29-20260625","article-title":"Chapter 9: Summarizing study characteristics and preparing for synthesis (chapter last updated October 2019","author":"McKenzie"},{"key":"R31-20260625","article-title":"Chapter 10: Analysing data and undertaking meta-analyses (chapter last updated November 2024)"},{"key":"R32-20260625","article-title":"Chapter 23: Including variants on randomized trials (chapter last updated October 2019)","author":"Higgins","journal-title":"Cochrane Handbook for Systematic Reviews of Interventions Version 6.5 (updated August 2024)"},{"key":"R33-20260625","article-title":"Chapter 14: Completing 'Summary of findings' tables and grading the certainty of the evidence (chapter last updated August 2023)","author":"Sch\u00fcnemann"},{"key":"R35-20260625","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1136\/bmj.39500.677199.AE","article-title":"Grading quality of evidence and strength of recommendations for diagnostic tests and strategies","volume":"336","author":"Sch\u00fcnemann","year":"2008","journal-title":"BMJ"},{"key":"R36-20260625","article-title":"Chapter III: Reporting the review (chapter last updaed August 2023)","author":"Cumpston","journal-title":"Cochrane Handbook for Systematic Reviews of Interventions version 6.5 (updated August 2024)"},{"key":"R37-20260625","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/S1473-3099(16)30004-4","article-title":"Ceftazidime-avibactam or best available therapy in patients with ceftazidime-resistant Enterobacteriaceae and Pseudomonas aeruginosa complicated urinary tract infections or complicated intra-abdominal infections (REPRISE): A randomised, pathogen-directed, phase 3 study","volume":"16","author":"Carmeli","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"R38-20260625","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/S1473-3099(24)00499-7","article-title":"Aztreonam-avibactam versus meropenem for the treatment of serious infections caused by Gram-negative bacteria (REVISIT): A descriptive, multinational, open-label, phase 3, randomised trial","volume":"25","author":"Carmeli","year":"2025","journal-title":"Lancet Infect Dis"},{"key":"R39-20260625","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1001\/jama.2018.0438","article-title":"Effect of Meropenem-Vaborbactam versus Piperacillin-Tazobactam on clinical cure or improvement and microbial eradication in complicated urinary tract infection: The TANGO I Randomized Clinical Trial","volume":"319","author":"Kaye","year":"2018","journal-title":"JAMA"},{"key":"R40-20260625","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1001\/jama.2022.17034","article-title":"Effect of Cefepime\/Enmetazobactam versus Piperacillin\/Tazobactam on clinical cure and microbiological eradication in patients with complicated urinary tract infection or acute pyelonephritis: A randomized clinical trial","volume":"328","author":"Kaye","year":"2022","journal-title":"JAMA"},{"key":"R41-20260625","doi-asserted-by":"crossref","first-page":"2543","DOI":"10.1093\/jac\/dkae254","article-title":"A randomized non-inferiority study comparing imipenem\/cilastatin\/relebactam with standard-of-care Gram-negative coverage in cancer patients with febrile neutropenia","volume":"79","author":"Chaftari","year":"2024","journal-title":"J Antimicrob Chemother"},{"key":"R42-20260625","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1016\/S1473-3099(19)30403-7","article-title":"Ceftolozane-tazobactam versus meropenem for treatment of nosocomial pneumonia (ASPECT-NP): A randomised, controlled, double-blind, phase 3, non-inferiority trial","volume":"19","author":"Kollef","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"R43-20260625","doi-asserted-by":"crossref","first-page":"107357","DOI":"10.1016\/j.ijid.2024.107357","article-title":"A phase III, randomized, controlled noninferiority trial to study the efficacy and safety of imipenem\/cilastatin\/relebactam (IMI\/REL) vs piperacillin\/tazobactam (PIP\/TAZ) in patients with hospital-acquired bacterial pneumonia (HABP) or ventilator-associated bacterial pneumonia (VABP)","volume":"153","author":"Li","year":"2025","journal-title":"Int J Infect Dis"},{"key":"R44-20260625","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1093\/jac\/dks523","article-title":"Comparative study of the efficacy and safety of ceftazidime\/avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infections in hospitalized adults: Results of a randomized, double-blind, Phase II trial","volume":"68","author":"Lucasti","year":"2013","journal-title":"J Antimicrob Chemother"},{"key":"R45-20260625","doi-asserted-by":"crossref","first-page":"5350","DOI":"10.1128\/AAC.00049-14","article-title":"Multicenter, double-blind, randomized, phase II trial to assess the safety and efficacy of ceftolozane-tazobactam plus metronidazole compared with meropenem in adult patients with complicated intra-abdominal infections","volume":"58","author":"Lucasti","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"R46-20260625","doi-asserted-by":"crossref","first-page":"6234","DOI":"10.1128\/AAC.00633-16","article-title":"Phase 2, dose-ranging study of relebactam with imipenem-cilastatin in subjects with complicated intra-abdominal infection","volume":"60","author":"Lucasti","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"R47-20260625","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1093\/cid\/ciw133","article-title":"Efficacy and safety of ceftazidime-avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infection: Results from a randomized, controlled, double-blind, phase 3 program","volume":"62","author":"Mazuski","year":"2016","journal-title":"Clin Infect Dis"},{"key":"R48-20260625","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1093\/cid\/ciz530","article-title":"RESTORE-IMI 1: A multicenter, randomized, double-blind trial comparing efficacy and safety of imipenem\/relebactam versus colistin plus imipenem in patients With Imipenem-nonsusceptible Bacterial Infections","volume":"70","author":"Motsch","year":"2020","journal-title":"Clin Infect Dis"},{"key":"R49-20260625","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.ijantimicag.2017.01.010","article-title":"A randomised, double-blind, phase 3 study comparing the efficacy and safety of ceftazidime\/avibactam plus metronidazole versus meropenem for complicated intra-abdominal infections in hospitalised adults in Asia","volume":"49","author":"Qin","year":"2017","journal-title":"Int J Antimicrob Agents"},{"key":"R50-20260625","doi-asserted-by":"crossref","first-page":"2616","DOI":"10.1093\/jac\/dkx139","article-title":"Prospective, randomized, double-blind, Phase 2 dose-ranging study comparing efficacy and safety of imipenem\/cilastatin plus relebactam with imipenem\/cilastatin alone in patients with complicated urinary tract infections","volume":"72","author":"Sims","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"R51-20260625","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1093\/cid\/civ097","article-title":"Ceftolozane\/tazobactam plus metronidazole for complicated intra-abdominal infections in an era of multidrug resistance: Results from a randomized, double-blind, phase 3 trial (ASPECT-cIAI)","volume":"60","author":"Solomkin","year":"2015","journal-title":"Clin Infect Dis"},{"key":"R52-20260625","doi-asserted-by":"crossref","first-page":"e4539","DOI":"10.1093\/cid\/ciaa803","article-title":"A randomized, double-blind, multicenter trial comparing efficacy and safety of imipenem\/cilastatin\/relebactam versus piperacillin\/tazobactam in adults with hospital-acquired or ventilator-associated bacterial pneumonia (RESTORE-IMI 2 Study)","volume":"73","author":"Titov","year":"2021","journal-title":"Clin Infect Dis"},{"key":"R53-20260625","doi-asserted-by":"crossref","first-page":"ofz149","DOI":"10.1093\/ofid\/ofz149","article-title":"Randomized trial of ceftazidime-avibactam versus meropenem for treatment of hospital-acquired and ventilator-associated bacterial pneumonia (REPROVE): Analyses per US FDA-specified end points","volume":"6","author":"Torres","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"R54-20260625","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1185\/03007995.2012.748653","article-title":"Efficacy and safety of ceftazidime-avibactam versus imipenem-cilastatin in the treatment of complicated urinary tract infections, including acute pyelonephritis, in hospitalized adults: Results of a prospective, investigator-blinded, randomized study","volume":"28","author":"Vazquez","year":"2012","journal-title":"Curr Med Res Opin"},{"key":"R55-20260625","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1016\/S0140-6736(14)62220-0","article-title":"Ceftolozane-tazobactam compared with levofloxacin in the treatment of complicated urinary-tract infections, including pyelonephritis: A randomised, double-blind, phase 3 trial (ASPECT-cUTI)","volume":"385","author":"Wagenlehner","year":"2015","journal-title":"Lancet"},{"key":"R56-20260625","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1093\/cid\/ciw378","article-title":"Ceftazidime-avibactam versus doripenem for the treatment of complicated urinary tract infections, including acute pyelonephritis: RECAPTURE, a phase 3 randomized trial program","volume":"63","author":"Wagenlehner","year":"2016","journal-title":"Clin Infect Dis"},{"key":"R57-20260625","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1056\/NEJMoa2304748","article-title":"Cefepime-taniborbactam in complicated urinary tract infection","volume":"390","author":"Wagenlehner","year":"2024","journal-title":"N Engl J Med"},{"key":"R58-20260625","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s40121-018-0214-1","article-title":"Effect and safety of meropenem-vaborbactam versus best-available therapy in patients with carbapenem-resistant enterobacteriaceae infections: The TANGO II randomized clinical trial","volume":"7","author":"Wunderink","year":"2018","journal-title":"Infect Dis Ther"},{"key":"R59-20260625","doi-asserted-by":"crossref","first-page":"e53","DOI":"10.1017\/ash.2021.217","article-title":"Evaluating the clinical effectiveness of new beta-lactam\/beta-lactamase inhibitor combination antibiotics: A systematic literature review and meta-analysis","volume":"1","author":"Wilson","year":"2021","journal-title":"Antimicrob Steward Healthc Epidemiol"},{"key":"R60-20260625","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/j.ajic.2024.02.016","article-title":"Effectiveness of novel \u03b2-lactams for Pseudomonas aeruginosa infection: A systematic review and meta-analysis","volume":"52","author":"Huang","year":"2024","journal-title":"Am J Infect Control"},{"key":"R61-20260625","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1186\/s13756-019-0624-1","article-title":"Choice of therapeutic interventions and outcomes for the treatment of infections caused by multidrug-resistant Gram-negative pathogens: A systematic review","volume":"8","author":"N\u00f8rgaard","year":"2019","journal-title":"Antimicrob Resist Infect Control"},{"key":"R62-20260625","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.3390\/antibiotics10091126","article-title":"Review of ceftazidime-avibactam for the treatment of infections caused by Pseudomonas aeruginosa","volume":"10","author":"Daikos","year":"2021","journal-title":"Antibiotics (Basel)"},{"key":"R63-20260625","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1093\/jac\/dkad280","article-title":"Efficacy and safety of ceftazidime\/avibactam in patients with infections caused by \u03b2-lactamase-producing Gram-negative pathogens: A pooled analysis from the Phase 3 clinical trial programme","volume":"78","author":"Torres","year":"2023","journal-title":"J Antimicrob Chemother"},{"key":"R64-20260625","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/YAPL9347","article-title":"Ceftazidime with avibactam for treating severe aerobic Gram-negative bacterial infections: Technology evaluation to inform a novel subscription-style payment model","volume":"28","author":"Harnan","year":"2024","journal-title":"Health Technol Assess"},{"key":"R65-20260625","article-title":"Treatment of Antimicrobial-Resistant Gram-Negative Infections","author":"Tamma","journal-title":"Clin Infect Dis. 403"},{"key":"R66-20260625","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1164\/rccm.201607-1447ED","article-title":"The 2016 guidelines for hospital-acquired and ventilator-associated pneumonia. A selection correction?","volume":"194","author":"Govindan","year":"2016","journal-title":"Am J Respir Crit Care Med"},{"key":"R67-20260625","doi-asserted-by":"crossref","first-page":"1700582","DOI":"10.1183\/13993003.00582-2017","article-title":"International ERS\/ESICM\/ESCMID\/ALAT guidelines for the management of hospital-acquired pneumonia and ventilator-associated pneumonia: Guidelines for the management of hospital-acquired pneumonia (HAP)\/ventilator-associated pneumonia (VAP) of the European Respiratory Society (ERS), European Society of Intensive Care Medicine (ESICM), European Society of Clinical Microbiology and Infectious Diseases (ESCMID) and Asociaci\u00f3n Latinoamericana del T\u00f3rax (ALAT)","volume":"50","author":"Torres","year":"2017","journal-title":"Eur Respir J"},{"key":"R69-20260625","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1590\/1806-9282.64.03.253","article-title":"Efficacy and safety of ceftazidime-avibactam in the treatment of complicated intra-abdominal infections (CIAIs) and complicated urinary tract infections (CUTIs): A meta-analysis of randomized controlled trials","volume":"64","author":"Zhang","year":"2018","journal-title":"Rev Assoc Med Bras (1992)"},{"key":"R70-20260625","doi-asserted-by":"crossref","first-page":"388","DOI":"10.3390\/antibiotics9070388","article-title":"Ceftazidime-avibactam combination therapy compared to ceftazidime-avibactam monotherapy for the treatment of severe infections due to carbapenem-resistant pathogens: A systematic review and network meta-analysis","volume":"9","author":"Fiore","year":"2020","journal-title":"Antibiotics (Basel)"},{"key":"R71-20260625","doi-asserted-by":"crossref","first-page":"e01052","DOI":"10.1128\/AAC.01052-20","article-title":"Is Ceftazidime\/avibactam an option for serious infections due to extended-spectrum-\u03b2-lactamase- and ampc-producing enterobacterales? A systematic review and meta-analysis","volume":"65","author":"Isler","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"R72-20260625","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1089\/sur.2024.137","article-title":"The surgical infection society guidelines on the management of intra-abdominal infection: 2024 update","volume":"25","author":"Huston","year":"2024","journal-title":"Surg Infect (Larchmt)"},{"key":"R73-20260625","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/j.idc.2009.06.008","article-title":"Pharmacokinetics and pharmacodynamics of antibacterial agents","volume":"23","author":"Levison","year":"2009","journal-title":"Infect Dis Clin North Am"},{"key":"R74-20260625","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1007\/s40121-023-00773-6","article-title":"Cefiderocol, a siderophore cephalosporin, as a treatment option for infections caused by carbapenem-resistant enterobacterales","volume":"12","author":"Kaye","year":"2023","journal-title":"Infect Dis Ther"},{"key":"R75-20260625","doi-asserted-by":"crossref","first-page":"107266","DOI":"10.1016\/j.ijantimicag.2024.107266","article-title":"A systematic review of the pharmacokinetics and pharmacodynamics of novel beta-lactams and beta-lactam with beta-lactamase inhibitor combinations for the treatment of pneumonia caused by carbapenem-resistant Gram-negative bacteria","volume":"64","author":"Rando","year":"2024","journal-title":"Int J Antimicrob Agents"},{"key":"R76-20260625","doi-asserted-by":"crossref","first-page":"5090","DOI":"10.3390\/ijms21145090","article-title":"Molecular mechanisms, epidemiology, and clinical importance of \u03b2-lactam resistance in enterobacteriaceae","volume":"21","author":"De Angelis","year":"2020","journal-title":"Int J Mol Sci"},{"key":"R77-20260625","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.3390\/pathogens10121638","article-title":"\u03b2-lactam Resistance in Pseudomonas aeruginosa: Current status, future prospects","volume":"10","author":"Glen","year":"2021","journal-title":"Pathogens"},{"key":"R78-20260625","doi-asserted-by":"crossref","first-page":"107028","DOI":"10.1016\/j.micpath.2024.107028","article-title":"Comparative genome analysis reveals putative and novel antimicrobial resistance genes common to the nosocomial infection pathogens","volume":"197","author":"Sahayarayan","year":"2024","journal-title":"Microb Pathog"},{"key":"R79-20260625","doi-asserted-by":"crossref","first-page":"e0089021","DOI":"10.1128\/AAC.00890-21","article-title":"KPC-mediated resistance to ceftazidime-avibactam and collateral effects in Klebsiella pneumoniae","volume":"65","author":"Findlay","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"R80-20260625","doi-asserted-by":"crossref","first-page":"e02097","DOI":"10.1128\/AAC.02097-16","article-title":"Emergence of ceftazidime-avibactam resistance due to plasmid-borne bla (KPC-3) mutations during treatment of carbapenem-resistant Klebsiella pneumoniae infections","volume":"61","author":"Shields","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"R81-20260625","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1089\/mdr.2018.0414","article-title":"Alliance of efflux pumps with \u03b2-lactamases in multidrug-resistant klebsiella pneumoniae isolates","volume":"25","author":"Maurya","year":"2019","journal-title":"Microb Drug Resist"},{"key":"R82-20260625","doi-asserted-by":"crossref","first-page":"2460","DOI":"10.1093\/jac\/dkae265","article-title":"The contribution of porins to enterobacterial drug resistance","volume":"79","author":"Davin-Regli","year":"2024","journal-title":"J Antimicrob Chemother"},{"key":"R83-20260625","doi-asserted-by":"crossref","first-page":"107081","DOI":"10.1016\/j.ijantimicag.2023.107081","article-title":"Activity of aztreonam\/avibactam and ceftazidime\/avibactam against enterobacterales with carbapenemase-independent carbapenem resistance","volume":"63","author":"Mushtaq","year":"2024","journal-title":"Int J Antimicrob Agents"},{"key":"R84-20260625","doi-asserted-by":"crossref","first-page":"e0248524","DOI":"10.1128\/spectrum.02485-24","article-title":"Molecular epidemiology and \u03b2-lactam resistance mechanisms of enterobacter cloacae complex isolates obtained from bloodstream infections, Kyoto, Japan","volume":"13","author":"Matsuo","year":"2025","journal-title":"Microbiol Spectr"},{"key":"R85-20260625","doi-asserted-by":"crossref","first-page":"8","DOI":"10.3390\/jcm8010008","article-title":"Detection of plasmid-mediated \u03b2-lactamase genes and Emergence of a novel AmpC (CMH-1) in enterobacter cloacae at a medical center in Southern Taiwan","volume":"8","author":"Ku","year":"2018","journal-title":"J Clin Med"},{"key":"R86-20260625","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1093\/jac\/dkaa447","article-title":"IS26-mediated amplification of blaOXA-1 and blaCTX-M-15 with concurrent outer membrane porin disruption associated with de novo carbapenem resistance in a recurrent bacteraemia cohort","volume":"76","author":"Shropshire","year":"2021","journal-title":"J Antimicrob Chemother"},{"key":"R87-20260625","doi-asserted-by":"crossref","first-page":"3209","DOI":"10.1093\/jac\/dkaa291","article-title":"Molecular and biochemical insights into the in vivo evolution of AmpC-mediated resistance to ceftolozane\/tazobactam during treatment of an MDR Pseudomonas aeruginosa infection","volume":"75","author":"Arca-Su\u00e1rez","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"R88-20260625","doi-asserted-by":"crossref","first-page":"10.1128\/AAC.00894","DOI":"10.1128\/AAC.00894-20","article-title":"Adding Insult to Injury: Mechanistic Basis for How AmpC Mutations Allow Pseudomonas aeruginosa To Accelerate Cephalosporin Hydrolysis and Evade Avibactam","volume":"64","author":"Slater","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"R89-20260625","doi-asserted-by":"crossref","first-page":"3023","DOI":"10.1093\/jac\/dkae326","article-title":"Impact of transferable \u03b2-lactamases and intrinsic AmpC amino acid substitutions on the activity of cefiderocol against wild-type and iron uptake-deficient mutants of Pseudomonas aeruginosa","volume":"79","author":"Gonz\u00e1lez-Pinto","year":"2024","journal-title":"J Antimicrob Chemother"},{"key":"R90-20260625","doi-asserted-by":"crossref","first-page":"e0079123","DOI":"10.1128\/aac.00791-23","article-title":"Natural protein engineering in the \u03a9-loop: the role of Y221 in ceftazidime and ceftolozane resistance in Pseudomonas-derived cephalosporinase","volume":"67","author":"Mack","year":"2023","journal-title":"Antimicrob Agents Chemother"},{"key":"R91-20260625","first-page":"9095203","article-title":"In vivo resistance to ceftolozane\/tazobactam in Pseudomonas aeruginosa arising by AmpC- and non-AmpC-mediated pathways","author":"Skoglund","year":"2018","journal-title":"Case Rep Infect Dis 2018"},{"key":"R92-20260625","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1590\/1806-9282.64.03.253","article-title":"Efficacy and safety of ceftazidime-avibactam in the treatment of complicated intra-abdominal infections (CIAIs) and complicated urinary tract infections (CUTIs): A meta-analysis of randomized controlled trials","volume":"64","author":"Zhang","year":"2018","journal-title":"Rev Assoc Med Bras (1992)"},{"key":"R93-20260625","doi-asserted-by":"crossref","first-page":"e0010921","DOI":"10.1128\/JB.00109-21","article-title":"Mutational activation of antibiotic-resistant mechanisms in the absence of major drug efflux systems of Escherichia coli","volume":"203","author":"Cho","year":"2021","journal-title":"J Bacteriol"},{"key":"R94-20260625","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.3390\/antibiotics10101164","article-title":"Pseudomonas aeruginosa mexR and mexEF antibiotic efflux pump variants exhibit increased virulence","volume":"10","author":"Vaillancourt","year":"2021","journal-title":"Antibiotics (Basel)"},{"key":"R95-20260625","doi-asserted-by":"crossref","first-page":"e14487","DOI":"10.1111\/1751-7915.14487","article-title":"Antibiotic influx and efflux in Pseudomonas aeruginosa: Regulation and therapeutic implications","volume":"17","author":"Wu","year":"2024","journal-title":"Microb Biotechnol"}],"container-title":["Journal of Global Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/jgid.jgid_133_25","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T16:25:28Z","timestamp":1786724728000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/jgid.jgid_133_25"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":88,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.4103\/jgid.jgid_133_25","relation":{},"ISSN":["0974-777X","0974-8245"],"issn-type":[{"value":"0974-777X","type":"print"},{"value":"0974-8245","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"2025-05-11","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-09-25","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}